BeOne Medicines (BEIGF) Other Non-Current Assets (2015 - 2026)

BeOne Medicines (BEIGF) has reported Other Non-Current Assets for 12 consecutive years, with $109.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Assets fell 32.24% year-over-year to $109.6 million in Q2 2026; TTM through Jun 2026 was $109.6 million, a 32.24% decrease from a year earlier, with the FY2025 full-year figure at $102.4 million, down 36.18% from the prior year.
• Other Non-Current Assets was $109.6 million for Q2 2026 at BeOne Medicines, up from $104.2 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $201.2 million in Q3 2024 and troughed at $3.9 million in Q2 2022.
• A 5-year average of $135.5 million and a median of $144.2 million in 2023 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets sank 60.32% in 2022 and soared 3645.85% in 2023, its largest moves.
• Over 5 years, Other Non-Current Assets stood at $175.7 million in 2022, then slipped by 28.65% to $125.4 million in 2023, then gained by 28.02% to $160.5 million in 2024, then sank by 36.18% to $102.4 million in 2025, then climbed by 6.99% to $109.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $109.6 million (Q2 2026), $104.2 million (Q1 2026), and $102.4 million (Q4 2025), per Business Quant data.